Search company, investor...

Afferent

afferentcorp.com

Founded Year

2000

Stage

Corporate Minority | Alive

Total Raised

$4M

About Afferent

Afferent Corporation, based in Providence, Rhode Island, is developing of a new class of medical devices to treat chronic neurologic dysfunction. Its lead technology enhances the function of mechanoreceptor cells involved in sensory perception as a means to restore brain function following a stroke, to address complications resulting from diabetic neuropathy, and to improve elderly balance. Afferent's development efforts are being pursued in collaboration with leading biomedical and clinical researchers throughout the United States. Building on this technology platform, Afferent aims to establish a leadership position in the emerging field of neurotherapeutic devices.

Headquarters Location

275 Westminster Street Suite 500

Providence, Rhode Island, 02903,

United States

401-453-9933

Missing: Afferent's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Afferent's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Afferent

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Afferent is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,898 items

Latest Afferent News

Irori, Afferent Link Solid Phase Synthesis Products with Combinational Chemistry Software

Feb 23, 2017

Irori (La Jolla, CA), a subsidiary of Discovery Partners International and a provider of drug discovery technologies, has signed a collaboration agreement with Afferent Systems Inc. (San Francisco), a provider of combinatorial chemistry design software. Under the terms of the agreement, Irori will immediately begin the distribution of Afferent software products. Afferent has developed an interface that links their software to the Irori solid phase synthesis products. The two companies will together define and develop future chemical synthesis and informatics technology and products. Financial terms of the deal were not disclosed. Irori's technology, called AccuTag, uses their novel "directed sorting" process and RF labeled microreactors to synthesize discrete compounds using a modification of the split-and-pool approach. It provides researchers with the means to synthesize large numbers of discrete compounds in quantities large enough to be useful for analytical testing and biological screenings. Afferent Systems Inc. develops, markets, and supports software systems that aid bench chemists and research IT staff in combinatorial chemistry. The company provides an integrated software solution for combinatorial chemistry informatics, including product structure generation, storage, and access; sample tracking and analytical information management; experiment planning and instrument control, all optionally using an Oracle-based enterprise-wide database. "Many of our customers are already using both the Afferent and Irori products and have expressed an interest in having the products seamlessly linked," said Richard K. Brown, VP of business development at Irori. Brown believes that linking these two leading combinatorial chemistry products also provides a natural basis for technology and product enhancement and expansion. Irori is a developer of combinatorial chemistry systems designed to accelerate drug discovery and the identification of novel compounds. For more information: Richard K. Brown, VP of Business Development, Irori, 11149 North Torrey Pines Rd., La Jolla, CA 92037. Tel: 619-546-1300. Fax: 619-546-3083. Email: info@irori.com. Like what you are reading? Sign up for our free newsletter SIGN ME UP By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy .

Afferent Frequently Asked Questions (FAQ)

  • When was Afferent founded?

    Afferent was founded in 2000.

  • Where is Afferent's headquarters?

    Afferent's headquarters is located at 275 Westminster Street, Providence.

  • What is Afferent's latest funding round?

    Afferent's latest funding round is Corporate Minority.

  • How much did Afferent raise?

    Afferent raised a total of $4M.

  • Who are the investors of Afferent?

    Investors of Afferent include Stryker, Boston University Technology Development, Nitta, Slater Technology Fund, PJC and 5 more.

  • Who are Afferent's competitors?

    Competitors of Afferent include NeuroPace, MicroTransponder, Tepha, Endologix, Spinal Restoration and 13 more.

Compare Afferent to Competitors

Veryan Medical Logo
Veryan Medical

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology has been proven to enhance clinical performance by improving flow conditions in, and the biomechanical performance of, stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide improved flow conditions and more flexibility, kink and fracture resistance than other nitinol stents. Veryan's Research & Development facility is located in Galway, Ireland.

V
Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

R
Reva Medical

REVA Medical develops interventional medical devices that leverage the company's stent designs and biomaterials to improve the treatment of vascular disease. Its flagship product is called MOTIV, a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product is utilized for the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The company was founded in 1998 and is based in San Diego, California.

MicroTransponder Logo
MicroTransponder

MicroTransponder is a global medical device company committed to developing research-based neuroscience solutions. The company focuses on restoring independence and dignity for people suffering from neurological conditions that impair sensory and motor function. MicroTransponder's FDA-approved Vivistim® Paired VNS™ System is a clinically-proven medical technology that generates more improvement in upper limb function than rehabilitation alone for stroke survivors after 6 weeks of in-clinic therapy. MicroTransponder was founded in 2007 and is based in Austin, Texas.

S
Satiety

Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.